Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 14/20 | 0.50 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.41 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24378019 | 0.92 | SIRT1 (0.48) | SIRT1SIRT3SIRT2POLB | |
| SCHEMBL26938751 | 0.90 | DGAT1 (0.40) | SIRT1DGAT1SOAT2CYP2C9SOAT1 | |
| SCHEMBL24378147 | 0.89 | SIRT1 (0.48) | SIRT1SIRT3SIRT2DGAT1SOAT2 | |
| SCHEMBL24378118 | 0.85 | SIRT1 (0.65) | SIRT1SIRT3SIRT2TDP1 | |
| SCHEMBL26938829 | 0.85 | SIRT1 (0.65) | SIRT1SIRT3SIRT2TDP1 | |
| SCHEMBL24378125 | 0.85 | SIRT1 (0.65) | SIRT1SIRT3SIRT2TDP1 | |
| SCHEMBL24378120 | 0.82 | SIRT1 (0.47) | SIRT1SIRT3SIRT2TDP1 | |
| SCHEMBL26938749 | 0.81 | POLB (0.44) | SIRT1CYP2C9POLB | |
| SCHEMBL24377971 | 0.79 | SIRT1 (0.43) | SIRT1SIRT3SIRT2POLB | |
| SCHEMBL24378153 | 0.78 | TDP1 (0.45) | SIRT1SIRT3SIRT2CYP2C9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| WO-2022087433-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | CKMT1A; CKMT1B, PHKG1, PCK1 | SIRT1 935/4885SIRT3 493/4885SIRT2 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.